Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs: A Retrospective Analysis among Managed Care Patients with Chronic Myelogenous Leukaemia
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Objectives Identify treatment interruptions and non-adherence with imatinib; examine the clinical and patient characteristics related to treatment interruptions and non-adherence; and estimate the association between treatment interruptions and non-adherence with imatinib and healthcare costs for US managed care patients with chronic myeloid leukaemia (CML). Methods This retrospective analysis utilised electronic healthcare claims data from a US managed care provider. Adult patients with CML (as determined by International Classification of Diseases, ninth revision, Clinical Modification [ICD-9-CM] diagnosis code) were identified who began treatment with imatinib from 1 June 2001 through 31 March 2004. Treatment interruptions (i.e. failure to refill imatinib within 30 days from the run-out date of the prior prescription) were identified during the 12-month follow-up period. Medication possession ratio (MPR), calculated as total days' supply of imatinib divided by 365, was also examined. Healthcare costs (i.e. paid amounts for all prescription medications and medical services received, including health plan and patient liability) were examined in three ways: (i) total healthcare costs; (ii) total healthcare costs exclusive of imatinib costs; and (iii) total medical costs. All costs were converted to US dollars (2004 values) using the medical component of the Consumer Price Index. MPR was modelled using ordinary least squares regression. Presence of treatment interruptions was…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“One study reported total annual costs of $119 416,74 while the other gave a subgroup analysis based on classified adherence levels.33”
From Economic impact of medication non-adherence by disease groups: a systematic review (2018) · cites this paper as [33]
Experimental — accuracy not yet measuredIn the citing paper
“In general, the lowest two adherence subgroups (<50% and 50%–90%) reported the highest total healthcare costs ($162 699 and $67 838).”
From Economic impact of medication non-adherence by disease groups: a systematic review (2018) · cites this paper as [33]
In the citing paper
“Low adherence to treatment may influence its efficacy and increase health service use and associated costs (Haynes et al, 1977; Darkow et al, 2007).”
From Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain (2012) · cites this paper as Darkow et al, 2007
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Horne, R., & Weinman, J. (1999) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(99)00057-4 · Cited by 2,201
Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost
Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005) · Medical Care · doi:10.1097/01.mlr.0000163641.86870.af · Cited by 1,729
The assessment of refill compliance using pharmacy records: Methods, validity, and applications
Steiner, J. F., & Prochazka, A. V. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(96)00268-5 · Cited by 1,193
Adherence to Antiretroviral Therapy in Sub-Saharan Africa and North America: A Meta-analysis
Mills, E. J., Nachega, J. B., Buchan, I., Orbinski, J., Attaran, A., Singh, S., Rachlis, B., Wu, P., Cooper, C., Thabane, L., et al. (2006) · JAMA · doi:10.1001/jama.296.6.679 · Cited by 899
The logged dependent variable, heteroscedasticity, and the retransformation problem
Manning, W. G. (1998) · Journal of Health Economics · doi:10.1016/s0167-6296(98)00025-3 · Cited by 877
Imatinib Mesylate — A New Oral Targeted Therapy
Savage, D. G., & Antman, K. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmra013339 · Cited by 844
Adherence to Therapy With Oral Antineoplastic Agents
Partridge, A. H. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.9.652 · Cited by 584
Research works printed but not linked: 4
- Deininger, 2005, Hematology (Am Soc Hematol Educ Program), 174-, 82
- Merante, 2005, Haematologica, 90, 979
- Schultz, 2005, Am J Manag Care, 11, 306
- Shalansky, 2002, Ann Pharmacother, 36, 1532, 10.1345/aph.1C044 · doi:10.1345/aph.1c044 · Paper page
Cited by
Economic impact of medication non-adherence by disease groups: a systematic review
Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-016982 · Cited by 900
“Two studies evaluated the effects of medication non-adherence in cancer.(33) 74 One study reported total annual costs of $119 416,(74) while the other gave a subgroup analysis based on classified adherence levels.”
BackgroundMarin, D., Bazeos, A., Mahon, F.-X., Eliasson, L., Milojkovic, D., Bua, M., Apperley, J. F., Szydlo, R., Desai, R., Kozlowski, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3087 · Cited by 909
Hershman, D. L., Shao, T., Kushi, L. H., Buono, D., Tsai, W. Y., Fehrenbacher, L., Kwan, M., Gomez, S. L., & Neugut, A. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1132-4 · Cited by 870
“A similar lack of adherence occurs with oral medications, such as Gleevec, for gastrointestinal stromal tumors or chronic myelogenous leukemia [34, 35 ].”
BackgroundNoens, L., van Lierde, M.-A., De Bock, R., Verhoef, G., Zachée, P., Berneman, Z., Martiat, P., Mineur, P., Van Eygen, K., MacDonald, K., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196543 · Cited by 616
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes
Noel, R. A., Braun, D. K., Patterson, R. E., & Bloomgren, G. L. (2009) · Diabetes Care · doi:10.2337/dc08-1755 · Cited by 435
Metadata
- Authors
- Darkow, T., Henk, H. J., Thomas, S. K., Feng, W., Baladi, J.-F., Goldberg, G. A., Hatfield, A., & Cortes, J.
- Affiliations
- Novartis (United States) (US)
- Corresponding author
- Darkow, Theodore
- Venue
- PharmacoEconomics
- Published
- 2007
- Volume
- 25
- Issue
- 6
- Pages
- 481-496
- ISSN
- 1170-7690 (ISSN-L)
- OpenAlex
- W1606656369
- Cited by
- 271
- References
- 50
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 6 · 2023: 6 · 2022: 9 · 2021: 13 · 2020: 16 · 2019: 17 · 2018: 15 · 2017: 18 · 2016: 11 · 2015: 26 · 2014: 23 · 2013: 30 · 2012: 27
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PharmacoEconomics (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- H2020 European Research Council
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Keywords
- imatinib, chronic myeloid leukemia, treatment interruption, medication non-adherence, medication possession ratio, health care costs, managed care, concomitant medications, sex differences, starting dose, prescription refills, patient characteristics, cost-effectiveness, quality of care, patient satisfaction, patient-provider communication, medication adherence interventions
- MeSH terms
- Imatinib Mesylate, Adolescent, Adult, Aged, Antineoplastic Agents, Benzamides, Female, Humans, Male, Managed Care Programs, Middle Aged, Piperazines, Drug Prescriptions, Pyrimidines, Retrospective Studies, United States, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Treatment Refusal, Drug Costs, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs: A Retrospective Analysis among Managed Care Patients with Chronic Myelogenous Leukaemia. https://app.cochat.ai/papers/10.2165/00019053-200725060-00004
- The paper
- Darkow, T., Henk, H. J., Thomas, S. K., Feng, W., Baladi, J.-F., Goldberg, G. A., Hatfield, A., & Cortes, J. (2007). Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs: A Retrospective Analysis among Managed Care Patients with Chronic Myelogenous Leukaemia. PharmacoEconomics. https://doi.org/10.2165/00019053-200725060-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.